SomnoMed Limited
(ASX:SOM) says strong growth in the sales of its sleep apnea devices has lifted third quarter revenue by 32 per cent compared to last year.
Global sales were up by 21 per cent led by strong growth of over 27 per cent in the North American region.
The company is seeing this dramatic growth in direct sales as it moves away from third party licensee sales.
The extra cash generated is being used to digitalise factory processes and integrate new Canadian products into the business.
SomnoMed recorded a net profit of $158,000 to the end of December 2015.
